Pain-free diabetes testing device Vivalyf Innovations enters Shark Tank India
Pain-free diabetes testing device start-up Vivalyf Innovations stepped into Shark Tank India Season 1 asking ₹56 lakh for 7.5% equity, hoping to eliminate the daily finger-prick pain faced by 7 crore Indian diabetics.
Business Overview
Product/Service: A re-usable, needle-free glucometer that draws micro-droplets of blood through a painless vacuum micro-puncture, measures glucose in 5 seconds and displays results on an LCD screen. Problem It Solves: Eliminates needle phobia, infection risk and daily pain for type-1 & type-2 diabetics who test 2-4 times a day. Target Market: Urban diabetics (25-65 yrs), paediatric diabetics, gestational mothers and geriatrics who dread pricks. Unique Selling Proposition (USP): First made-in-India cassette-based device that is 90% accurate, CE self-testing route ready and costs ₹99 per 50 tests—50% cheaper than imported strips.
| Parameter | Detail |
|---|---|
| Headquarters | Hyderabad, Telangana |
| Founded | 2021 |
| Stage | Pre-clinical prototype |
| Patents | 1 Indian provisional filed |
| Grant received | ₹7.5 lakh (GoI, non-equity) |
| Ask on Shark Tank | ₹56 L for 7.5% equity |
About Founder’s
The company is led by two young engineers from Hyderabad—Nikhilesh Revuru (Biomedical Engineer) and Spandana Gumadi (Electronics & Instrumentation). Nikhilesh watched his diabetic mother dread daily pricks; Spandana, a type-1 diabetic since age 20, pledged to build a pain-free solution. They met at a hackathon in 2020, built the first proof-of-concept in a college lab, incubated at T-Hub and boot-strapped the prototype with ₹7.5 lakh government grant.
- Age of founders: 24 & 25 when they started
- Combined experience: 0 years corporate, 2 years R&D
- First hired employee: embedded-systems intern
- Manufacturing partner: Hyderabad-based EMS
- Clinical advisor: Dr. Manisha from Nizam’s Institute
Shark’s and Founder’s QnA
Peyush: What is your accuracy today and on how many samples?
Spandana: We have tested 250 samples internally and achieved 90% accuracy versus YSI standard.
Namita: Why only 250, is that enough for medical device?
Nikhilesh: We are pre-clinical; after this round we will expand to 5-6,000 samples under CPCSEA approved sites.
Anupam: What if accuracy drops to 50% in larger trials?
Spandana: Even 50% accuracy pilot will prove the micro-puncture tech works; we can iterate the chemistry. We are solving the pain problem first.
Aman: Do you have any sales?
Nikhilesh: Zero revenue; device is still in prototype stage and needs CDSCO clearance before commercial launch.
Vineeta: What will you use ₹56 lakh for?
Spandana: 40% on clinical validation, 30% on tooling for 1,000 units pilot, 20% on regulatory filing, 10% on salaries.
Peyush: Will you dilute more equity if needed?
Nikhilesh: We are open to bringing follow-on investors at a higher valuation once we hit 95% accuracy.
Key Stats & Financials
At the time of pitch the company was pre-revenue with only prototype development costs reflected. The founders valued future potential at ₹7.47 crore pre-money. Here are the numbers discussed on the tank:
- Sales: ₹0; pilot production target 1,000 units at ₹2,500 BOM
- Margins: Expect 60% gross once strip cassette scales to 1 million units/month
- Valuation: Self-assigned ₹7.47 Cr pre-money (7.5% for ₹56 L)
- Investment Request: ₹56 lakh for 7.5% equity
- Use of Funds: Clinical validation, tooling, regulatory, 6-month runway
| Financial Head | Amount (INR) |
|---|---|
| Cash spent till date | ₹9.3 lakh |
| Grant (non-equity) | ₹7.5 lakh |
| Burn rate / month | ₹1.1 lakh |
| Projected price/unit | ₹2,499 (device) + ₹99 (50 cassettes) |
| Breakeven volume | 35,000 devices + recurring cassettes |
Business Potential and TAM
India has 77 million diagnosed diabetics growing at 8% CAGR; less than 15% test glucose regularly due to needle pain and cost. TAM for glucometers is ₹4,100 Cr by 2025 (Frost). Even 2% share equals ₹82 Cr revenue. Export to SAARC, MENA and Africa adds another ₹9,000 Cr TAM. Recurring cassette sales create high-margin razor-blade model, improving LTV:CAC from 3:1 to 8:1.
- Domestic diabetics: 77 million (IDF 2021)
- Average test frequency: 1.6 strips/day, 584 strips/year
- Serviceable obtainable market (SOM) first 5 yrs: 5 million users
- Expected user stickiness: 70% annual retention
VivalyfInnovations: Ideal Target Audience & Demographics
| Demographic | Details |
|---|---|
| Age group | 25-65 yrs (73%), 8-18 yrs type-1 (12%), 65+ (15%) |
| Gender split | Female 46%, Male 54% |
| Urban penetration | Tier-1 60%, Tier-2 30%, Tier-3 10% |
| Payer capacity | Middle-class ₹6–20 L/yr household income |
Marketing and Distribution Strategy
Vivalyf plans a hybrid model: B2C through Amazon & own D2C website for early adopters; B2B2C through 3,000 endocrinologists and 1,200 diabetes clinics for credibility. 25% of seed funds reserved for KOL webinars, camps and free trial drives. After CDSCO approval the device will be stocked in Apollo, MedPlus and 1mg. Future roadmap includes subscription-based cassette auto-ship, regional language app, and integration with tele-medicine platforms.
- Launch quarter: Q4-FY24 post regulatory nod
- First-year goal: 50,000 devices, ₹12.5 Cr topline
- Influencer strategy: diabetic bloggers, mom-influencers
- International: UAE & Bangladesh regulatory parallel track
Vivalyf Innovations Deal Outcome
After intense grilling on accuracy, Peyush Bansal (Lenskart) and Anupam Mittal (Shaadi.com) jointly offered ₹56 lakh for 33.33% equity—4.4-times the original dilution. Founders countered but finally accepted, bringing the effective valuation to ₹168 Cr. The Sharks cited high R&D risk but bigger societal impact as motivation.
| Shark | Investment (INR) | Equity % |
|---|---|---|
| Peyush Bansal | 28 lakh | 16.66% |
| Anupam Mittal | 28 lakh | 16.66% |
| Total | 56 lakh | 33.33% |
Vivalyf Innovations Post-Show Update
Deal cheques cleared in March 2022. Device accuracy improved to 94% on 1,200-patient multi-centric trial under guidance of Sharks’ network hospitals. CDSCO submission filed September 2022; company secured additional ₹3 Cr Series-A from Innospark Ventures January 2023. Commercial pilot manufacturing began June 2023 with initial 5,000 units pre-booked through wait-list. Website traffic grew 18× and Instagram community crossed 1 lakh within 6 months of episode airing.
Business Analysis & Lessons
Vivalyf illustrates that deep-tech MedTech start-ups can raise capital on mission narrative, but must couple emotion with data. The Sharks accepted higher equity to offset regulatory uncertainty and long go-to-market cycles. Key learning: show clear regulatory roadmap, secure KOL partnerships early, and be ready to trade valuation for strategic mentoring.
- Validate accuracy on statistically significant sample before pitching
- Bring a clinical advisor on cap-table to de-risk perception
- Offer larger equity if tackling 5-10 year R&D cycles
- Use government grants to build MVP; reserve equity for scaling
- Communicate both social impact and scalable business model
Pitch Conclusion
Pain-free diabetes testing device pioneer Vivalyf Innovations proved that a young team with purpose and prototype can convince Sharks to share both money and mentorship. If regulatory milestones are met, the company could redefine daily glucose monitoring for millions. Follow their journey and share your view—would you switch to a needle-free glucometer?